Navigation Links
Aptuit Drug Discovery & Development Center In Verona, Italy Hits 100th Client Milestone

GREENWICH, Conn., Nov. 8, 2012 /PRNewswire/ -- Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the number of clients placing work at The Aptuit Center for Drug Discovery & Development in Verona, Italy has reached 100, giving the site a strong vote of confidence from the marketplace.

(Logo: )

Mark Hembarsky, Vice President and Site Leader of the facility stated, "We are excited to have reached this important milestone of 100 clients at Aptuit Verona. In July of 2010, we started with one client, GlaxoSmithKline, following our acquisition of the site from them. Since that time, more and more clients have been recognizing that we have something unique and valuable to offer, and that we are certainly doing something right in helping them achieve their goals."

Mr. Hembarsky explained that in the two brief years since the acquisition, the Aptuit Verona facility has successfully made the transition from a single customer site to a dynamic drug discovery and development center attracting all types of clients – large, multinational pharmaceutical innovators, midsize and small pharma companies, biotechs and startups.

"Companies from the EU, North America, Asia and South America have placed projects with us covering numerous therapeutic areas," said Mr. Hembarsky. "We are proud that industry-leading companies like Pfizer Inc., Chiesi Farmaceutici, Sunovion Pharmaceuticals Inc., Boehringer Ingelheim, UCB, C10 Pharma, Autifony Therapeutics and GlaxoSmithKline are among the clients that have chosen to partner with Aptuit." He added that most clients have subsequently contracted repeat business with Aptuit and many have requested proposals for additional work before their initial project was completed.

"Our growth is a testimony to Aptuit's capabilities, and continued business inquiries are a source of great encouragement. Clients recognize that we offer the intelligence and insights of scientific professionals engaged in multidisciplinary activities, from integrated discovery, preclinical development, API and drug product development and clinical sciences through to clinical Proof of Concept.  Our 'heads for science' are accustomed to taking a big picture approach, applying what we call Integrated Knowledge. Because of our legacy as an R&D engine of a leading pharmaceutical company, we understand the total process of drug discovery and development and we apply that understanding to all work that we perform – whether it's fully integrated services or a specific stand-alone project. Our teams of highly experienced and knowledgeable drug development professionals can anticipate potential problems and offer preemptive solutions, allowing clients to mitigate risks, save time and reduce costs. Our 'hearts for service' are devoted to understanding what is important to each project and delivering, as promised, on time and in full, ultimately helping each client achieve their goals," said Mr. Hembarsky.

Mr. Needleman concluded, "We are very pleased that clients understand that they are getting the best of both worlds when they work with Aptuit Verona – the efficiency of an experienced CRO combined with the scientific expertise of a large pharmaceutical research and development engine. We're now at 100, and still counting."

Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGOO (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors.

For more information about Aptuit, visit

CONTACT:  Maria Garvey, +1-1-914-747-1400,


Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference
2. Discovery Labs Reports Third Quarter 2012 Financial Results
3. BD Completes Sale of Majority of Discovery Labware Unit
4. Discovery of New "Youth Pill" Revealed At International Scientific Conference
5. Drug Discovery in Rare Diseases
6. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
7. Initiating Rare Disease Drug Discovery Projects
8. Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
9. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
10. Drug Discovery Technologies, BCC Research
11. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
Post Your Comments:
(Date:11/27/2015)... 27, 2015 Ein neuer ... Krebs.   --> Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz ...   Clinical Cancer Research vom ... Cancer Research vom 6. November 2015 berichtet. ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... carrier-grade software solutions and services which empower organizations through communication analytics, announced today ... them effectively monitor and manage their service quality. , Proteus® VoIP QMS ...
(Date:11/29/2015)... ... 29, 2015 , ... "I struggled for years with pain every day. I ... would love to do, I missed. We moved back home from living out of ... first. They have changed my life drastically. I love all of the people involved ...
(Date:11/29/2015)... ... November 29, 2015 , ... Khanna Vision Institute based ... of Ophthalmology on November 25th 2015. Peer Certification by the Board is done ... specialty. Certification in Ophthalmology is first obtained after the completion of three years of ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion from ... designed specially for Final Cut Pro X. FCPX users can now ... modification controls. Destoying and creating chaotic distortion is now quick and simple, putting ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad ... has added Chris Hafey and Claude Hooton to its board of directors. The ... North America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus ...
Breaking Medicine News(10 mins):